CINECA IRIS Institutional Research Information System

MORETTO, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.027
AS - Asia 1.038
EU - Europa 729
SA - Sud America 217
AF - Africa 62
OC - Oceania 2
Totale 4.075
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.976
SG - Singapore 363
CN - Cina 276
IT - Italia 222
HK - Hong Kong 199
BR - Brasile 174
SE - Svezia 97
GB - Regno Unito 93
DE - Germania 90
VN - Vietnam 83
BG - Bulgaria 64
FR - Francia 38
CA - Canada 33
FI - Finlandia 30
RU - Federazione Russa 30
IN - India 28
CI - Costa d'Avorio 25
AR - Argentina 20
JP - Giappone 16
TR - Turchia 16
PL - Polonia 15
KR - Corea 14
BD - Bangladesh 13
AT - Austria 10
NG - Nigeria 10
SN - Senegal 10
ZA - Sudafrica 9
ES - Italia 8
MX - Messico 8
NL - Olanda 7
UA - Ucraina 7
ID - Indonesia 6
IQ - Iraq 6
CZ - Repubblica Ceca 5
SA - Arabia Saudita 5
CL - Cile 4
MA - Marocco 4
PK - Pakistan 4
CO - Colombia 3
EC - Ecuador 3
HN - Honduras 3
IE - Irlanda 3
PE - Perù 3
PY - Paraguay 3
VE - Venezuela 3
AU - Australia 2
BO - Bolivia 2
LT - Lituania 2
PA - Panama 2
PT - Portogallo 2
UY - Uruguay 2
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BW - Botswana 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KY - Cayman, isole 1
MY - Malesia 1
NO - Norvegia 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 4.075
Salva come PNG Salva come JPEG
Città #
Ashburn 235
Hong Kong 197
Dallas 192
Singapore 190
Fairfield 177
Santa Clara 172
Woodbridge 153
Chandler 111
Shanghai 95
Seattle 84
Houston 81
Cambridge 75
Wilmington 70
Sofia 63
New York 59
Ann Arbor 58
Los Angeles 51
Beijing 47
Boardman 44
London 43
Munich 38
Florence 37
Princeton 30
Lawrence 27
Pisa 27
Abidjan 25
Milan 23
Hefei 21
Ottawa 21
Ho Chi Minh City 19
Serra 19
Medford 18
Redondo Beach 17
Cascina 16
Bremen 15
Dearborn 15
São Paulo 15
Tokyo 15
Des Moines 14
Frankfurt am Main 14
Ogden 14
Seoul 14
Turku 14
Warsaw 14
Lancaster 13
Istanbul 12
Buffalo 10
Dakar 10
Düsseldorf 10
Lagos 10
Rio de Janeiro 10
Seacroft 10
Helsinki 9
Vienna 9
Hanoi 8
Dong Ket 7
Fuzhou 7
Nanjing 7
Orem 7
San Diego 7
Fortaleza 6
Redwood City 6
Brooklyn 5
Denver 5
Montreal 5
Phoenix 5
Poplar 5
Verona 5
Atlanta 4
Baghdad 4
Chennai 4
Curitiba 4
Genoa 4
Guarulhos 4
Johannesburg 4
Paris 4
Shenyang 4
Toronto 4
Asunción 3
Belo Horizonte 3
Boston 3
Brasília 3
Bromsgrove 3
Coreglia Antelminelli 3
Dublin 3
Haiphong 3
Hebei 3
Lima 3
Mumbai 3
Nanchang 3
Norwalk 3
Nuremberg 3
Qingdao 3
Quanzhou 3
Riyadh 3
Rome 3
San Francisco 3
Sorocaba 3
Turin 3
Anzio 2
Totale 2.972
Salva come PNG Salva come JPEG
Nome #
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 169
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 154
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 148
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 147
The landscape of alterations in DNA damage response pathways in colorectal cancer 147
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 144
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 141
A still missing piece of the FIRE-3 puzzle 140
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 137
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 137
Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer 136
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 136
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 135
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 135
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 134
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 131
BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases 130
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features 127
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 121
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 118
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 112
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients 110
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 109
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation 104
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 104
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 102
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study 101
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 97
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 91
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 90
Upper transversal hepatectomy with double hepatic vein resection and reconstruction to treat colorectal cancer liver metastases at the hepatocaval confluence: a strategy to achieve R0 liver-sparing resection 88
null 85
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 83
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy 70
null 65
Totale 4.178
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.406
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.406
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021198 0 0 0 0 0 64 8 12 40 9 16 49
2021/2022241 3 2 6 1 46 53 2 9 13 22 15 69
2022/2023417 42 68 38 29 41 44 7 30 60 0 55 3
2023/2024337 23 25 49 21 48 47 26 10 10 10 33 35
2024/20251.188 12 35 30 58 107 146 118 52 110 138 115 267
2025/2026964 96 190 231 205 147 95 0 0 0 0 0 0
Totale 4.178